Literature DB >> 23723898

7-Chloro-5-methyl-2-phenyl-pyrazolo-[1,5-a]pyrimidine.

Ibtissam Bassoude1, Sabine Berteina-Raboin, El Mokhtar Essassi, Gérald Guillaumet, Lahcen El Ammari.   

Abstract

The fused pyrazole and pyrimidine rings in the title compound, C13H10ClN3, are almost coplanar, their planes being inclined to one another by 0.8 (2)°. The mean plane of the fused ring system is nearly coplanar with the phenyl ring, as indicated by the dihedral angle between their planes of 9.06 (7)°.

Entities:  

Year:  2013        PMID: 23723898      PMCID: PMC3648278          DOI: 10.1107/S1600536813009896

Source DB:  PubMed          Journal:  Acta Crystallogr Sect E Struct Rep Online        ISSN: 1600-5368


Related literature

For pharmacological and biochemical properties of pyra­zolo­[1,5-a]pyrimidine derivatives, see: Selleri et al. (2005 ▶); Almansa et al. (2001 ▶); Suzuki et al. (2001 ▶), Chen et al. (2004 ▶). For related structures, see: Senga et al. (1981 ▶).

Experimental

Crystal data

C13H10ClN3 M = 243.69 Monoclinic, a = 6.5993 (2) Å b = 12.6166 (4) Å c = 13.8702 (5) Å β = 100.131 (2)° V = 1136.84 (6) Å3 Z = 4 Mo Kα radiation μ = 0.31 mm−1 T = 296 K 0.41 × 0.32 × 0.21 mm

Data collection

Bruker X8 APEXII area-detector diffractometer 16957 measured reflections 2925 independent reflections 2521 reflections with I > 2σ(I) R int = 0.024

Refinement

R[F 2 > 2σ(F 2)] = 0.035 wR(F 2) = 0.103 S = 1.06 2925 reflections 154 parameters H-atom parameters constrained Δρmax = 0.23 e Å−3 Δρmin = −0.23 e Å−3 Data collection: APEX2 (Bruker, 2009 ▶); cell refinement: SAINT (Bruker, 2009 ▶); data reduction: SAINT; program(s) used to solve structure: SHELXS97 (Sheldrick, 2008 ▶); program(s) used to refine structure: SHELXL97 (Sheldrick, 2008 ▶); molecular graphics: ORTEP-3 for Windows (Farrugia, 2012 ▶); software used to prepare material for publication: PLATON (Spek, 2009 ▶) and publCIF (Westrip, 2010 ▶). Click here for additional data file. Crystal structure: contains datablock(s) I, global. DOI: 10.1107/S1600536813009896/rz5056sup1.cif Click here for additional data file. Structure factors: contains datablock(s) I. DOI: 10.1107/S1600536813009896/rz5056Isup2.hkl Click here for additional data file. Supplementary material file. DOI: 10.1107/S1600536813009896/rz5056Isup3.cml Additional supplementary materials: crystallographic information; 3D view; checkCIF report
C13H10ClN3F(000) = 504
Mr = 243.69Dx = 1.418 Mg m3
Monoclinic, P21/nMo Kα radiation, λ = 0.71073 Å
Hall symbol: -P 2ynCell parameters from 2925 reflections
a = 6.5993 (2) Åθ = 3.0–28.7°
b = 12.6166 (4) ŵ = 0.31 mm1
c = 13.8702 (5) ÅT = 296 K
β = 100.131 (2)°Block, colourless
V = 1136.84 (6) Å30.41 × 0.32 × 0.21 mm
Z = 4
Bruker X8 APEXII area-detector diffractometer2521 reflections with I > 2σ(I)
Radiation source: fine-focus sealed tubeRint = 0.024
Graphite monochromatorθmax = 28.7°, θmin = 3.0°
φ and ω scansh = −6→8
16957 measured reflectionsk = −17→17
2925 independent reflectionsl = −18→18
Refinement on F2Primary atom site location: structure-invariant direct methods
Least-squares matrix: fullSecondary atom site location: difference Fourier map
R[F2 > 2σ(F2)] = 0.035Hydrogen site location: inferred from neighbouring sites
wR(F2) = 0.103H-atom parameters constrained
S = 1.06w = 1/[σ2(Fo2) + (0.0523P)2 + 0.2738P] where P = (Fo2 + 2Fc2)/3
2925 reflections(Δ/σ)max = 0.001
154 parametersΔρmax = 0.23 e Å3
0 restraintsΔρmin = −0.23 e Å3
Geometry. All e.s.d.'s (except the e.s.d. in the dihedral angle between two l.s. planes) are estimated using the full covariance matrix. The cell e.s.d.'s are taken into account individually in the estimation of e.s.d.'s in distances, angles and torsion angles; correlations between e.s.d.'s in cell parameters are only used when they are defined by crystal symmetry. An approximate (isotropic) treatment of cell e.s.d.'s is used for estimating e.s.d.'s involving l.s. planes.
Refinement. Refinement of F2 against all reflections. The weighted R-factor wR and goodness of fit S are based on F2, conventional R-factors R are based on F, with F set to zero for negative F2. The threshold expression of F2 > σ(F2) is used only for calculating R-factors(gt) etc. and is not relevant to the choice of reflections for refinement. R-factors based on F2 are statistically about twice as large as those based on F, and R- factors based on all data will be even larger.
xyzUiso*/Ueq
C10.07651 (19)0.69856 (10)0.25074 (9)0.0344 (3)
C2−0.0283 (2)0.72024 (10)0.32394 (10)0.0393 (3)
H2−0.14590.76220.31210.047*
C30.0426 (2)0.67836 (11)0.41889 (10)0.0420 (3)
C40.3143 (2)0.59912 (10)0.36620 (9)0.0369 (3)
C50.4894 (2)0.54075 (11)0.36126 (9)0.0398 (3)
H50.57080.50410.41200.048*
C60.51851 (19)0.54836 (10)0.26417 (9)0.0349 (3)
C70.68242 (19)0.49912 (10)0.21982 (9)0.0353 (3)
C80.8475 (2)0.44870 (11)0.27861 (11)0.0423 (3)
H80.85460.44680.34620.051*
C91.0010 (2)0.40136 (12)0.23699 (13)0.0502 (4)
H91.11120.36840.27680.060*
C100.9911 (2)0.40282 (13)0.13685 (13)0.0522 (4)
H101.09400.37060.10920.063*
C110.8287 (2)0.45210 (13)0.07785 (12)0.0521 (4)
H110.82150.45280.01030.063*
C120.6755 (2)0.50072 (12)0.11910 (11)0.0448 (3)
H120.56710.53470.07890.054*
C13−0.0778 (3)0.69939 (16)0.49944 (12)0.0599 (4)
H13A−0.19460.74300.47480.090*
H13B0.00840.73520.55250.090*
H13C−0.12390.63340.52240.090*
N10.24981 (16)0.63830 (8)0.27118 (7)0.0332 (2)
N20.37353 (16)0.60790 (9)0.20808 (8)0.0357 (2)
N30.20986 (19)0.61941 (10)0.43971 (8)0.0432 (3)
Cl10.00409 (5)0.74223 (3)0.13336 (2)0.04662 (13)
U11U22U33U12U13U23
C10.0348 (6)0.0302 (5)0.0367 (6)0.0020 (5)0.0021 (5)0.0041 (5)
C20.0389 (7)0.0361 (6)0.0427 (7)0.0089 (5)0.0061 (5)0.0022 (5)
C30.0462 (7)0.0413 (7)0.0385 (6)0.0091 (6)0.0078 (5)−0.0005 (5)
C40.0393 (6)0.0370 (6)0.0326 (6)0.0047 (5)0.0014 (5)0.0011 (5)
C50.0401 (7)0.0423 (7)0.0351 (6)0.0103 (5)0.0012 (5)0.0014 (5)
C60.0331 (6)0.0323 (6)0.0382 (6)0.0011 (5)0.0029 (5)−0.0004 (5)
C70.0318 (6)0.0319 (6)0.0421 (6)−0.0016 (5)0.0061 (5)−0.0006 (5)
C80.0379 (7)0.0412 (7)0.0459 (7)0.0033 (5)0.0021 (5)−0.0029 (5)
C90.0359 (7)0.0483 (8)0.0647 (10)0.0074 (6)0.0044 (6)−0.0021 (7)
C100.0412 (8)0.0508 (8)0.0691 (10)0.0031 (6)0.0219 (7)−0.0026 (7)
C110.0527 (8)0.0576 (9)0.0508 (8)0.0019 (7)0.0224 (7)0.0033 (7)
C120.0414 (7)0.0502 (8)0.0436 (7)0.0053 (6)0.0095 (6)0.0043 (6)
C130.0659 (10)0.0735 (11)0.0433 (8)0.0281 (9)0.0176 (7)0.0038 (7)
N10.0334 (5)0.0318 (5)0.0338 (5)0.0036 (4)0.0042 (4)0.0023 (4)
N20.0344 (5)0.0360 (5)0.0368 (5)0.0026 (4)0.0068 (4)0.0024 (4)
N30.0479 (6)0.0474 (6)0.0335 (5)0.0130 (5)0.0053 (5)0.0004 (5)
Cl10.0463 (2)0.0521 (2)0.04017 (19)0.00949 (14)0.00399 (14)0.01307 (13)
C1—C21.3533 (18)C7—C81.3940 (18)
C1—N11.3610 (16)C8—C91.386 (2)
C1—Cl11.7055 (13)C8—H80.9300
C2—C31.4197 (19)C9—C101.379 (2)
C2—H20.9300C9—H90.9300
C3—N31.3201 (18)C10—C111.377 (2)
C3—C131.504 (2)C10—H100.9300
C4—N31.3519 (17)C11—C121.389 (2)
C4—C51.3818 (18)C11—H110.9300
C4—N11.4019 (16)C12—H120.9300
C5—C61.3966 (18)C13—H13A0.9600
C5—H50.9300C13—H13B0.9600
C6—N21.3503 (16)C13—H13C0.9600
C6—C71.4727 (17)N1—N21.3532 (15)
C7—C121.3897 (19)
C2—C1—N1118.58 (11)C10—C9—C8120.34 (14)
C2—C1—Cl1123.81 (10)C10—C9—H9119.8
N1—C1—Cl1117.61 (9)C8—C9—H9119.8
C1—C2—C3119.48 (12)C11—C10—C9119.88 (14)
C1—C2—H2120.3C11—C10—H10120.1
C3—C2—H2120.3C9—C10—H10120.1
N3—C3—C2122.62 (12)C10—C11—C12120.10 (15)
N3—C3—C13117.87 (12)C10—C11—H11119.9
C2—C3—C13119.50 (13)C12—C11—H11119.9
N3—C4—C5132.85 (12)C11—C12—C7120.65 (14)
N3—C4—N1122.10 (11)C11—C12—H12119.7
C5—C4—N1105.05 (11)C7—C12—H12119.7
C4—C5—C6105.62 (11)C3—C13—H13A109.5
C4—C5—H5127.2C3—C13—H13B109.5
C6—C5—H5127.2H13A—C13—H13B109.5
N2—C6—C5112.96 (11)C3—C13—H13C109.5
N2—C6—C7119.48 (11)H13A—C13—H13C109.5
C5—C6—C7127.56 (11)H13B—C13—H13C109.5
C12—C7—C8118.62 (12)N2—N1—C1127.17 (10)
C12—C7—C6121.13 (12)N2—N1—C4112.96 (10)
C8—C7—C6120.25 (12)C1—N1—C4119.86 (11)
C9—C8—C7120.39 (14)C6—N2—N1103.41 (10)
C9—C8—H8119.8C3—N3—C4117.35 (11)
C7—C8—H8119.8
  7 in total

1.  A short history of SHELX.

Authors:  George M Sheldrick
Journal:  Acta Crystallogr A       Date:  2007-12-21       Impact factor: 2.290

2.  Synthesis and SAR of a new series of COX-2-selective inhibitors: pyrazolo[1,5-a]pyrimidines.

Authors:  C Almansa; A F de Arriba; F L Cavalcanti; L A Gómez; A Miralles; M Merlos; J García-Rafanell; J Forn
Journal:  J Med Chem       Date:  2001-02-01       Impact factor: 7.446

3.  Synthesis and biological evaluations of condensed pyridine and condensed pyrimidine-based HMG-CoA reductase inhibitors.

Authors:  M Suzuki; H Iwasaki; Y Fujikawa; M Sakashita; M Kitahara; R Sakoda
Journal:  Bioorg Med Chem Lett       Date:  2001-05-21       Impact factor: 2.823

4.  Insight into 2-phenylpyrazolo[1,5-a]pyrimidin-3-yl acetamides as peripheral benzodiazepine receptor ligands: synthesis, biological evaluation and 3D-QSAR investigation.

Authors:  Silvia Selleri; Paola Gratteri; Camilla Costagli; Claudia Bonaccini; Annarella Costanzo; Fabrizio Melani; Gabriella Guerrini; Giovanna Ciciani; Barbara Costa; Francesca Spinetti; Claudia Martini; Fabrizio Bruni
Journal:  Bioorg Med Chem       Date:  2005-08-15       Impact factor: 3.641

5.  Synthesis and antischistosomal activity of certain pyrazolo[1,5-a]pyrimidines.

Authors:  K Senga; T Novinson; H R Wilson; R K Robins
Journal:  J Med Chem       Date:  1981-05       Impact factor: 7.446

6.  Design of 2,5-dimethyl-3-(6-dimethyl-4-methylpyridin-3-yl)-7-dipropylaminopyrazolo[1,5-a]pyrimidine (NBI 30775/R121919) and structure--activity relationships of a series of potent and orally active corticotropin-releasing factor receptor antagonists.

Authors:  Chen Chen; Keith M Wilcoxen; Charles Q Huang; Yun-Feng Xie; James R McCarthy; Thomas R Webb; Yun-Fei Zhu; John Saunders; Xin-Jun Liu; Ta-Kung Chen; Haig Bozigian; Dimitri E Grigoriadis
Journal:  J Med Chem       Date:  2004-09-09       Impact factor: 7.446

7.  Structure validation in chemical crystallography.

Authors:  Anthony L Spek
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2009-01-20
  7 in total
  1 in total

1.  N-(2-Bromo-4-methyl-phen-yl)-2-(5-methyl-2-phenyl-pyrazolo-[1,5-a]pyrimidin-7-yl)acetamide.

Authors:  Ibtissam Bassoude; Sabine Berteina-Raboin; El Mokhtar Essassi; Gérald Guillaumet; Lahcen El Ammari
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2013-05-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.